Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood

International Journal of Cancer

Volumn 110, Issue 1, 2004, Pages 87-93

  Menu Branthomme, Axelle ^a   Rubino, Carole ^a   Shamsaldin, Akhtar ^a   Hawkins, Michael M ^b   Grimaud, Emmanuel ^a   Dondon, Marie Gabrielle ^a   Hardiman, Claire ^a   Vassal, Gilles ^a   Campbell, Sarah ^g   Panis, Xavier ^c   Daly Schveitzer, Nicolas ^d   Lagrange, Jean Leon ^e   Zucker, Jean Michel ^f   Chavaudra, Jean ^a   Hartman, Olivier ^a   De Vathaire, Florent ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUT JEAN GODINOT   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f INSTITUT CURIE   (France)

^g Thames Cancer Registry ^*  (United Kingdom)

Author keywords

Childhood cancer; Epidemiology; Second primary cancer; Soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; PROCARBAZINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; FRANCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; POPULATION RESEARCH; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; SEX DIFFERENCE; SOFT TISSUE SARCOMA; SOLID TUMOR; STANDARDIZATION; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY DOSAGE; RISK; SARCOMA;

EID: 11144356226     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20002     Document Type: Article

References (32)

1. Tucker MA, Meadows AT, Boice JD, Hoover RN, Fraumeni JF Jr. Cancer risk following treatment of childhood cancer. In: Boice JD, Fraumeni JF Jr. Radiation carcinogenesis: epidemiology and biological significance. New York: Raven Press, 1984. 211-24.
2. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987;56: 339-47.
3. Olsen JH, Garwicz S, Hertz H, Jonmundsson G, Langmark F, Lanning M, Li SO, Moe PJ, Moller T, Sankila R. Second malignant neoplasms after cancer in childhood or adolescence. Br Med J 1993;307:1030-36.
4. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robinson LL. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst 2001;93:618-29.
5. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MM, Seddon JM, Tarbell M, Fraumeni JF, Li FP. Cancer incidence after retinoblastoma. JAMA 1997;278:1262-67.
6. Little MP, de Vathaire F, Shamsaldin A, Oberlin O, Campbell S, Grimaud E, Chavaudra J, Haylock RGF, Muirhead CR. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer 1998; 78:269-75.
7. Le Vu B, de Vathaire F, Shamsaldin A, Hawkins MM, Grimaud E, Hardiman C, Diallo I, Vassal G, Bessa E, Campbell S, Panis X, Daly-Schveitzer N, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumors during childhood. Int J Cancer 1998; 77:370-77.
8. De Vathaire F, Hawkins M, Campbell S, Oberlin O, Raquin MA, Schlienger JY, Shamsaldim A, Bell J, Hardiman C, Lagrange JL, Daly-Schveitzer N, Panis X, et al. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer 1999;79:1884-93.
9. De Vathaire F, Hardiman C, Shamsaldin A, Campbell S, Grimaud E, Hawkins M, Raquin M, Oberlin O, Diallo I, Zucker JM, Panis X, Lagrange JL, et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 1999;159:2713-19.
10. Grimaud E, Shamsaldin A, Lamon A, Hardiman C, de Vathaire F, Chavaudra J. Programme original de calcul de dose appliqué à l'étude des seconds cancers. Bull Cancer Radiother 1994;81:482.
11. Diallo I, Lamon A, Shamsaldin A, Grimaud E, de Vathaire F, Chavaudra J. Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapy. Radiother Oncol 1996;38:269-71.
12. Shamsaldim A, Grimaud E, Hardiman C, Diallo I, de Vathaire F, Chavaudra J. Dose distribution throughout the body from radiotherapy for Hodgkin's disease in childhood. Radiother Oncol 1998;49:85-90.
13. Ligot L, Diallo I, Shamsaldin A, Chavaudra J, Bonaiti-Pellie C, de Vathaire F. Individualized phantom based on CT slices and auxological data (ICTA) for dose estimations following radiotherapy for skin haemangiomas in childhood. Radiother Oncol 1998;49:279-85.
14. Shamsaldin A, Lundell M, Ligot L, Diallo I, Chavaudra J, de Vathaire F. Estimation of the radiation dose from radiotherapy for skin hemangiomas in childhood: the ICTA software for epidemiology. Phys Med Biol 2000;45:3589-99.
15. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powel J. Cancer incidence in five continents, vol. 6. Lyon: International Agency for Research on Cancer, 1992.
16. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powel J. Trends in cancers incidence and mortality. Lyon: International Agency for Research on Cancer, 1993.
17. De Vathaire F, Koscielny S, Rezvani A, Laplanche A, Esteve J, Ferlay J. Estimation de l'incidence des cancers en France 1983-1987. Paris : Les éditions INSERM, 1996, 144p.
18. Menegoz F, Black RJ, Arveux P, Magne V, Ferlay J, Buemi A, Carli PM, Chapelin G, Faivre J, Gignoux M, Grosclaude P, Mace-Lesec'h J, et al. Cancer incidence and mortality in France in 1975-95. Eur J Cancer Prev 1997;6:442-66.
19. Breslow NE, Day NE. Statistical methods in cancer research: the design and analysis of cohort studies, vol.2. Lyon: International Agency for Research on Cancer, 1987. 394p.
20. Preston DL, Lubin JH, Pierce DA, McConney ME. EPICURE. Generalized regression models for epidemiological data. HiroSoft International Corporation: Seattle (WA), 1991.
21. Moolgavkar SH, Venzon DJ. A method for computing profile likelihood based confidence bounds. Ann Statist 1987;15:346-59.
22. Kellerer AM, Barclay D. Age dependencies in the modeling of radiation carcinogenesis. Radiat Prot Dosim 1992;41:273.
23. Breslow NE, Day NE. Statistical methods in cancer research: the analysis of cases-control studies, vol. 1. Lyon: International Agency for Research on Cancer, 1980: 338p.
24. Little MP, Hawkins MM, Shore RE, Charles MW, Hildreth NG. Time variations in the risk of cancer following irradiation in childhood. Radiat Res 1991:126:304-16.
25. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. New York: United Nations, 1996. 272p.
26. Tucker MA, d'Angio GJ, Boice JD, Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588-93.
27. Hawkins MM, Kinnier Wilson LM, Burton HS, Potok MHN, Winter DL, Marsden HB, Stovall MA. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88:270-78.
28. Karlsson P, Holmberg E, Johansson KA, Kindblom LG, Carstensen J, Wallgren A. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996;38:25-31.
29. Van Lseeuwen FE, Somers R, Hart AA. Splenectomy in Hodgkin's disease and second leukemias. Lancet 1987;2:210-11.
30. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P. Malignant tumors occurring after treatment of aplastic anaemia. N Engl J Med 1993;329:1152-57.
31. Garwicz S, Anderson H, Olsen JH, Dollner H, Hertz H, Jonmundsson J, Langmark F, Lanning M, Moller T, Sankila R, Tulinius H. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. Int J Cancer 2000;88:672-78.
32. Sieber SM, Correa P, Dalgard DW, Adamson RH. Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res 1978;38:2125-34.